||B-hEPCAM EL4||Catalog number||310713|
|Aliases||DIAR5, EGP-2, EGP40, ESA, HNPCC8, TROP1||Disease||Lymphoma|
|Tissue types||Lymphoma||Tissue||T lymphocyte|
The mouse Epcam gene was replaced by human EPCAM coding sequence in B-hEPCAM EL4 cells. Human EPCAM is highly expressed on the surface of B-hEPCAM EL4 cells.
B-hEPCAM EL4 cells have the capability to establish tumors in vivo and can be used for efficacy studies.
Gene targeting strategy for B-hEPCAM EL4 cells. The exogenous promoter and human EPCAM coding sequence was inserted to replace part of murine exon 4 and all of exons 5~7. The insertion disrupts the endogenous murine Epcam gene, resulting in a non-functional transcript.
Protein expression analysis
EPCAM expression analysis in B-hEPCAM EL4 cells by flow cytometry. Single cell suspensions from wild-type EL4 and B-hEPCAM EL4 cultures were stained with species-specific anti-EPCAM antibody. Human EPCAM was detected on the surface of B-hEPCAM EL4 cells but not wild-type EL4 cells. The 4-B04 clone of B-hEPCAM EL4 cells was used for in vivo experiments.
Tumor growth curve & Body weight changes
Subcutaneous homograft tumor growth of B-hEPCAM EL4 cells. B-hEPCAM EL4 cells (2x105) and wild-type EL4 cells (2x105) were subcutaneously implanted into C57BL/6 mice (female, 6-9-week-old, n=5). Tumor volume and body weight were measured twice a week. (A) Average tumor volume ± SEM. (B) Body weight (Mean± SEM). Volume was expressed in mm3 using the formula: V=0.5 X long diameter X short diameter2. As shown in panel A, B-hEPCAM EL4 cells were able to establish tumors in vivo and can be used for efficacy studies.Animals with tumor volume over 3000mm3 in the control group were euthanized.
Protein expression analysis of tumor cells